Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Retatrutide shows potentially superior weight loss numbers but remains investigational, with Phase 3 trials still underway
YN: Writing original draft
Liu, S.-M
Spire Institute
Glucagon-like Peptide-1 (GLP-1) Agonists Recent Developments In June 2026, Viking Therapeutics announced on June 24 the initiation of its Phase 1 clinical trial evaluating VK3019, an investigational dual amylin and calcitonin receptor agonist (DACRA)
For the myotendinous junction, as a combination point of anatomical and structural particularities (largely reviewed in [124,125]) such a new therapy possibility might be particularly important given the still unresolved problem of being the weakest element in the muscletendon unit, (and bonetendon junctions as extremely specialized tissues in general)
US$ 22.74
US$ 24.67
US$ 20.36
